ClearNote Health

ClearNote Health is a San Diego-based healthtech company focused on early cancer detection, offering noninvasive blood-based tests (Avantect®) for pancreatic and ovarian cancers using its proprietary Virtuoso™ epigenomics platform, which combines 5hmC epigenomics, AI, and machine learning. The company's multi-cancer detection technology was selected for the National Cancer Institute's Vanguard Study, and it has raised over $185 million in total funding.